万古霉素全生命周期药代动力学:汇总群体分析与现行给药方案评估
本研究汇总14项研究构建万古霉素群体药代动力学模型,以经后月经年龄、体重和血清肌酐为协变量,模拟并比较不同患者亚组的稳态暴露。结果显示现行FDA与EMA给药方案在各亚组均无法达到满意稳态暴露,优化后提高FDA标签剂量可在各亚组实现一致目标达成且欠剂量与过剂量风险最小(±20%)。
要点
- 万古霉素清除率随年龄成熟与衰退,经后月经年龄46.4周达最大值50%,61.6岁降至50%。
- 现行FDA与EMA给药方案在不同患者亚组均未能达到满意稳态暴露。
- 优化后提高FDA标签剂量可在各亚组实现一致目标达成,欠/过剂量风险±20%。
核心结论
- 构建的万古霉素群体药代动力学模型可用于进一步开发按年龄和肾功能分层的给药方案,并通过治疗药物监测与贝叶斯预测实现个体化治疗。
研究设计与样本
- 基于14项不同患者人群研究的汇总群体药代动力学分析,使用NONMEM建模并模拟稳态暴露。
主要发现
- 最终模型以经后月经年龄、体重和血清肌酐为协变量。
- 35岁、70 kg、血清肌酐0.83 mg dL-1(73.4 µmol L-1)患者V1、V2、CL和Q2分别为42.9 L、41.7 L、4.10 L h-1和3.22 L h-1。
- 清除率随年龄成熟,经后月经年龄46.4周达最大值50%(5.31 L h-1 70 kg-1),61.6岁降至50%。
- 现行给药指南在各患者亚组均未能达到满意稳态暴露。
- 优化后提高FDA标签剂量可在各亚组实现一致目标达成,欠剂量与过剂量风险最小(±20%)。
关键数值与推荐
- FDA与EMA批准的两种药品标签剂量被模拟评估,优化剂量被推导。
临床怎么用
- 可基于年龄和肾功能分层设计万古霉素给药方案,并结合治疗药物监测与贝叶斯预测进行个体化调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Uncertainty exists regarding the optimal dosing regimen for vancomycin in different patient populations, leading to a plethora of subgroup-specific pharmacokinetic models and derived dosing regimens. We aimed to investigate whether a single model for vancomycin could be developed based on a broad dataset covering the extremes of patient characteristics. Furthermore, as a benchmark for current dosing recommendations, we evaluated and optimised the expected vancomycin exposure throughout life and for specific patient subgroups. METHODS: A pooled population-pharmacokinetic model was built in NONMEM based on data from 14 different studies in different patient populations. Steady-state exposure was simulated and compared across patient subgroups for two US Food and Drug Administration/European Medicines Agency-approved drug labels and optimised doses were derived. RESULTS: The final model uses postmenstrual age, weight and serum creatinine as covariates. A 35-year-old, 70-kg patient with a serum creatinine level of 0.83 mg dL-1 (73.4 µmol L-1) has a V1, V2, CL and Q2 of 42.9 L, 41.7 L, 4.10 L h-1 and 3.22 L h-1. Clearance matures with age, reaching 50% of the maximal value (5.31 L h-1 70 kg-1) at 46.4 weeks postmenstrual age then declines with age to 50% at 61.6 years. Current dosing guidelines failed to achieve satisfactory steady-state exposure across patient subgroups. After optimisation, increased doses for the Food and Drug Administration label achieve consistent target attainment with minimal (± 20%) risk of under- and over-dosing across patient subgroups. CONCLUSIONS: A population model was developed that is useful for further development of age and kidney function-stratified dosing regimens of vancomycin and for individualisation of treatment through therapeutic drug monitoring and Bayesian forecasting.
引用
- Colin PJ, Allegaert K, Thomson AH, et al. Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. Clin Pharmacokinet. 2019. PMID: 30656565. doi:10.1007/s40262-018-0727-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。